TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
ARAI

Arrive AI Inc.

Technology · Scientific & Technical Instruments · listed since 2025

0.2498$ +9.7% vs. previous close Closing price · As of: Sep 17, 2026
🔔 Watch stock
Add to watchlist

Assessment

Our Rating

A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.

Substance risk

We found at least one documented issue that threatens the company itself — regardless of how the stock is currently valued.

Why this colour

The auditor's going-concern qualification on the 2025 annual report is expressly described as unresolved in the quarterly report for March 31, 2026: at roughly $1 million of cash burn per month against roughly $7.1 million of liquidity (May 12, 2026), the cash on hand does not cover four quarters, and more than 90 percent of the $113,250 in revenue comes from a single customer. On top of that come a restatement of the Q2 and Q3 2025 quarterly reports, acknowledged material weaknesses in internal control, and two open Nasdaq deadlines (November 30, 2026 and January 19, 2027) — the survival of the company itself is therefore in question. The decision is yours.

What the thesis turns on

Assessment: Opportunities & Risks

Arrive AI is the label trap in its purest form: "AI" in the name, a serious product idea with a real patent portfolio — and underneath, filings that document a fight for survival: $113,250 of annual revenue (more than 90 percent from one customer) against a $12.8 million loss, a going-concern warning that the quarterly report calls "not alleviated," financing that raised the share count by 52 percent in four and a half months, and three Nasdaq notices with deadlines of November 30, 2026 and January 19, 2027. Whoever buys is buying an option on survival — not AI infrastructure with substance. Not investment advice.

Product & patents

The idea is serious: smart delivery stations for the autonomous last mile, a patent portfolio granted since 2017 (nine U.S. patents plus international filings) and paying pilot customers from medical logistics (including Hancock Health). But the AI features are only planned for the AP4/AP5 station generations; in operation are pilot installations of the 3rd generation (per the 10-K, April 15, 2026).

Cash cushion & time bought

The company has bought itself time: $9.6 million net in January 2026, roughly $7.1 million of liquidity as of May 12, 2026, a standstill with Streeterville through December 31, 2026 and an at-the-market program of up to $15 million (June 12, 2026). At roughly $1 million of monthly burn (2025), that lasts into 2027 depending on the pace — then new money is needed at whatever prices prevail.

Revenue reality

$113,250 of revenue in 2025, $89,000 of it consulting and more than 90 percent from a single customer (Hancock Health, per the 10-K); Q1 2026: $14,925. The "AI Services" in the company name are so far future tense without revenue. Operating expenses 2025: $10.5 million — that mismatch is the core number of this stock.

Liquidity & going concern

Going-concern opinion from the auditor on the 2025 accounts; the 10-Q as of March 31, 2026 declares the doubt "not alleviated." Cash of $2.1 million at year-end 2025 against ~$1 million of monthly burn; the remaining ~$19 million of the facility requires a $100 million market capitalization — more than three times the filing anchor of ~$29 million (June 11, 2026).

Dilution & financing structure

Conversion at min(reference price; 90 percent of the lowest 10-day VWAP, $0.25 floor): share count up from 34.2 million (December 31, 2025) to 51.9 million (May 15, 2026), +52 percent; per the 10-Q, another +63 percent possible. Add 2,937,500 pre-delivery shares for $588 and an ATM program that opens the next dilution source. The stock fell along the conversion staircase from $2.25 (January 26) to ~$0.53 (April).

Listing & reporting quality

Three Nasdaq notices within four months (MVPHS March 31, cured; minimum bid price, deadline November 30, 2026; MVPHS again, deadline January 19, 2027). Restatement of the Q2+Q3 2025 10-Qs over a misbooked conversion derivative (8-K Item 4.02, April 14, 2026) and admitted material weaknesses — of all places, in the accounting for the financing the company depends on.

Worth Noting

The stock landed on our desk via the SEC's fresh filings (8-K of July 24, 2026, second MVPHS notice from Nasdaq) — not via a metrics scanner: the company was not in our database before this research. No meaningful P/E or P/S; classic multiples mislead at this revenue level.

The market capitalization from the market-data feed deviated by more than 20 percent from the filing anchor and was not used; all price and valuation figures come from the filings ($13.00 fair value 01–05/2025; $2.63 on December 31, 2025; $0.797 on March 31, 2026; $0.56 on June 11, 2026 per the 424B5; market value ~$29 million = 51,859,347 × $0.56). Analyses are evergreen; daily prices are not a buy argument.

Not to be confused: Arrive AI (ARAI, delivery infrastructure out of Indiana) has nothing to do with Atai Life Sciences (ATAI, biotech). The name history DRONEDEK → Arrive Technology → Arrive AI is documented in the 10-K; the 1-for-4 reverse split of November 25, 2024 predates the listing, and all share counts are retroactively adjusted.

Stock Watch

This analysis is as of August 26, 2026. Stock Watch will tell you what's changed at ARAI since then.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Price history

Chart

Interactive price chart (TradingView).

52-week range: 0.222 $ to 6.30 $ · Last price: 0.2498 $ (As of: September 17, 2026)

Key figures

Key figures at a glance

Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.

Basics

Market Cap ?The value of the entire company on the market: share price times total shares outstanding. 0.02$B
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 52m
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 52.5%
Beta ?Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.

Performance

Perf. 1M ?Price performance over the last month. -38.50%
Perf. 3M ?Price performance over the last 3 months. -73.50%
Perf. 6M ?Price performance over the last 6 months. -93.60%
YTD Performance (%) ?Price performance since the start of the year (Year to Date). -83.30%
52-Week-High Distance ?How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high. -97.0%
Perf. 1Y ?Price performance over the last 12 months. -92.14%
Perf. 5Y ?Price performance over the last 5 years. -96.88%
Perf. Since Inception ?Price performance since the first available trading day (05/15/2025) — with a complete history, that is since the IPO. -98.11%

Technical Indicators

MA 38 Days ?Moving average of the last 38 trading days: the smoothed price path. A price above it signals short-term strength. 0.2443$
MA 50 Days ?Moving average of the last 50 trading days — the most widely watched medium-term trend line. 0.2726$
MA 200 Days ?Moving average of the last 200 trading days — the dividing line between a long-term uptrend and downtrend. 1.10$
RSI (14) ?Relative Strength Index over 14 days, scale 0 to 100: above 70 counts as overbought, below 30 as oversold. A hint on timing, not a verdict on the company. 50.1
Volatility 30 Days ?Price swings over the last 30 trading days, annualized. The higher the value, the more the price fluctuates. 70.0%
Volatility 250 Days ?Price swings over the last 250 trading days (roughly one market year), annualized. 142.4%

Calculated from the price history · as of 09/18/2026

Valuation

P/E ?Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
Forward P/E ?P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future. 0.0
PEG ?P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
P/B ?Price-to-book ratio: market value relative to book equity. 5.1
P/S ?Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
EV/EBITDA ?Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero. 0.0
Price/FCF ?Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.

Profitability

Gross Margin ?Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power. 100.0%
EBIT Margin ?EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
Net Margin ?Net margin: what's left of sales as profit after ALL costs, interest, and taxes. 0.0%
Return on Equity ?Return on equity: how much profit does the company generate per year on shareholders' equity? -398.1%
Return on Assets ?Return on assets: how much profit the company generates from its total assets (equity and debt combined). -81.7%

Balance Sheet & Safety

Equity Ratio ?Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
Debt/Equity ?Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity. 3.7
Altman Z″ ?Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks. warning zone -10.15
Piotroski ?Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag. 3 out of 9

Growth

Sales Growth Last Quarter ?Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY). 0.00%
EPS Growth Last Quarter ?Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY). 0.00%
Sales Growth (Year) ?Sales growth in the last fiscal year versus the year before.
Forward Sales Growth ?Sales growth analysts expect over the next 12 months — an estimate, not a guarantee. 650.00%
Forward EPS Growth ?Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage ?Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line. 4
RS Rating ?Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks. 1
EPS Rating ?Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth. 42
Fundamental Rating ?Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below. D (31 out of 100)

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Comparison

Industry comparison

The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.

Industry: Scientific & Technical Instruments

Industry comparison
Company Market cap ($B) P/E EV/EBITDA Gross Margin % EBIT Margin % Sales Growth (Year) % Perf. 1Y %
Arrive AI Inc. ARAI 0.0 0.0 100.0 -92.1
Keysight Technologies Inc KEYS 60.0 52.9 28.1 63.3 18.8 8.0 91.7
Coherent Inc COHR 58.7 130.0 34.5 37.5 13.6 23.4 186.2
Garmin Ltd GRMN 53.1 30.3 22.3 60.1 24.6 15.1 18.9
Teledyne Technologies Incorporated TDY 27.9 30.8 18.5 43.3 19.0 7.9 8.3
MKS Instruments Inc MKSI 17.5 47.7 19.3 46.9 16.1 9.6 99.6
Fortive Corp FTV 17.0 32.8 16.0 63.2 17.9 -17.5 15.2
Trimble Inc TRMB 13.4 29.4 53.7 71.8 15.9 -2.6 -28.0
Cognex Corporation CGNX 10.1 72.9 36.4 68.9 22.3 8.7 38.9
Median of companies shown 17.5 40.2 22.3 63.2 18.4 8.3 18.9

Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →

Fiscal years

Annual Figures

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

Revenue, operating income and net income per fiscal year $M

Revenue Operating income Net income

2021 · Revenue: 0 $M 2021 · Operating income: -2 $M 2021 · Net income: -2 $M 2022 · Revenue: 0 $M 2022 · Operating income: -2 $M 2022 · Net income: -2 $M 2023 · Revenue: 0 $M 2023 · Operating income: -5 $M 2023 · Net income: -7 $M 2024 · Revenue: 0 $M 2024 · Operating income: -5 $M 2024 · Net income: -5 $M 2025 · Revenue: 0 $M 2025 · Operating income: -10 $M 2025 · Net income: -13 $M
20212022202320242025
Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2021 0 -2 -2 -0.05 -1 3 3
2022 0 -2 -2 -0.08 -2 2 3
2023 0 -5 -7 -0.24 -3 0 1
2024 0 -5 -5 -0.15 -2 -1 1
2025 0 -10 -13 -0.40 -8 2 11

Quarters

Quarterly Figures

Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 0.0 $M Q4 2025: Q1 · 0.0 $M Q1 2025: Q2 · 0.1 $M Q2 2025: Q3 · 0.0 $M Q3 2025: Q4 · 0.0 $M Q4 2026: Q1 · 0.0 $M Q1 2026: Q2 · 0.0 $M Q2

Source: fundamental data

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -0.03 0 0 0
2025: Q1 -0.07 0 -1 -1
2025: Q2 -0.09 0 -5,153.80 -3 -3
2025: Q3 -0.04 0 -31,957.10 -1 -1
2025: Q4 -0.08 0 -26,146.70 -3 -4
2026: Q1 -0.18 0 -42,466.70 -3 -4
2026: Q2 -0.28 -211.10 0 -100.00 -3 -4

What Do These Terms Mean?

EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Compare with other stocks →

Screening

Appears in These Scanners

This stock currently matches 10 of our scanner strategies — each hit links to the scanner.

Best Hits

Research

Risk & Weakness

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Outlook

Analysts & Price Target

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Consensus
Analyst Ratings
Price Target (average) 1.00$
Distance to price 300.3% The price target sits 300.3% above the current price.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 -0.58 -0.58 – -0.58 0 1
12/31/2027 -0.31 -0.31 – -0.31 2 1

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Valuation

What is priced in?

Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.

A simplified model calculation — not a forecast and not a recommendation.

AI classification

AI Rating

Sells AI

Das einzige Produkt — die ALM-Plattform mit dem Arrive-Point-Netz — wird im 10-K ausdrücklich mit „AI Services“ als Erlössäule beschrieben und über laufende Abos verkauft (113.250 $ Umsatz 2025, 14.925 $ in Q1 2026); die KI-Datenmonetarisierung selbst ist laut 10-Q noch im Aufbau (ML erst für die Stationsgenerationen AP4/AP5 geplant).

View the full file — quotes, sources, reviewed filings
„Our integrated ALM Platform combines a physical Arrive Point™ Network (delivered as Network-as-a-Service), an ALM Marketplace for dynamic scheduling and transactional optimization and AI Services for data-driven insights and automation."

Unsere integrierte ALM-Plattform verbindet ein physisches Arrive-Point™-Netz (bereitgestellt als Network-as-a-Service), einen ALM-Marktplatz für dynamische Terminierung und Transaktionsoptimierung und AI Services für datengetriebene Erkenntnisse und Automatisierung.

10-K · 2026-04-15 · View SEC filing

„Data monetization via models and insights generated by machine learning and artificial intelligence (“ML” and “AI”)."

Datenmonetarisierung über Modelle und Erkenntnisse, die durch maschinelles Lernen und künstliche Intelligenz („ML“ und „AI“) erzeugt werden.

10-Q · 2026-05-15 · View SEC filing

„Our mission is to connect these systems through a universal ALM network of Arrive Points™—smart lockers and mini-cross-docks—powered by an AI-driven ALM platform."

Unsere Mission ist es, diese Systeme über ein universelles ALM-Netz aus Arrive Points™ — smarte Schließfächer und Mini-Umschlagpunkte — zu verbinden, angetrieben von einer KI-getriebenen ALM-Plattform.

10-Q · 2026-05-15 · View SEC filing

Filings Reviewed: 10-K 2026-04-15 · 10-Q 2026-05-15 · 8-K 2026-07-24 · 424B5 2026-06-12 · 8-K 2026-06-05 · 8-K 2026-05-18

Rated on July 27, 2026 · How the Rating Is Built

Growth

Growth Score

Ten checks against the annual reports — each one passed counts a point.

4 of 10 Weak growth
  • Revenue grows by more than 15% a year over three years no data
  • More than 10% revenue growth is expected for the coming year 650.0%
  • Share count grows by less than 3% a year 2.4%
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
  • Gross margin at 40% or higher and without meaningful erosion no data
  • Goodwill from acquisitions does not grow faster than revenue 0.0%
  • Net debt below twice EBITDA failed
  • Operating cash flow covers the profits of the last three years 11 m
  • Return on capital at 15% or higher, or up versus two years ago -244.0%
  • Insiders hold at least 10% or are net buyers 60.5%

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Quality check

AAQS

3/10

The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).

  • Sales growth 10Y > 5%
  • Exp. sales growth 3Y > 5% 326.4%
  • EBIT growth 10Y > 5%
  • Exp. EBIT growth 3Y > 5% 326.4%
  • Net debt < 4x EBIT
  • EBIT positive, 10Y straight 0
  • Max. EBIT decline < 50%
  • Return on equity > 15% -582.3%
  • ROCE > 15% -243.9%
  • Expected return > 10% 77.7%

View stocks with the full AAQS score · Read the methodology at AlleAktien

Source: fundamental data

The company

About the Company

Arrive AI Inc., ein Technologieunternehmen, entwirft und implementiert ein kommerziell tragfähiges System aus smartem Briefkasten und Plattform in den USA.

Employees
50
Headquarters
Fishers, IN
Address
9100 Fall View Drive, 46037 Fishers, United States
Phone
463 270 0092
IPO Date
05/15/2025
ISIN
US04272H2040

Management

Management
Name Title Birth Year
Daniel Steven O'Toole Founder, CEO & Chairman 1965
Mark D. Hamm COO & Director 1967
John Ritchison Attorney, Secretary, General Counsel & Director 1951
Neerav Shah Chief Strategy Officer & Director 1973
Piyush Phadke Chief Financial Officer 1979
Kylie Conway Senior Marketing & Communications Manager
Ian Geise Head of Commercialization 1972
Lora O'Toole Vice President of Business Development 2000

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Filings

Company Filings (8-K)

An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).

  • 09/08/2026 Arrive AI Inc. (ARAI): Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
  • 08/19/2026 Arrive AI Inc. (ARAI): Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Financial Statements and Exhibits SEC ↗
  • 08/12/2026 Arrive AI Inc. (ARAI): Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Financial Statements and Exhibits SEC ↗
  • 07/31/2026 Arrive AI Inc. (ARAI): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers SEC ↗
  • 07/24/2026 Arrive AI Inc. (ARAI): Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing SEC ↗

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?